For citizens

For companies

For medical specialists

EMA seeks views of public during its safety review of valproate

Registration opens for first public hearing

The European Medicines Agency (EMA) is inviting citizens to share their experience with valproate – a medicine that treats epilepsy, bipolar disorder and migraine – at its very first public hearing on 26 September 2017 at the Agency’s offices in London.

More information on the following link:

EMA seeks views of public during its safety review of valproate